Here you go, Brig:
The current Altman Z-score (which is based on the company's current financials and market value of equity, and is unaffected by the exchange the company is listed on) is 5.13.
Recall that scores below 1.8 indicate financial distress and high risk of bankruptcy within the next 2 years; scores from 1.81 to 2.99 are a gray area; and scores above 3.00 indicate financial strength. So a score of 5.13 indicates significant financial strength.
That AYSI would have a high Z-score here makes intuitive sense, if you consider that it is profitable, has a healthy amount of cash and positive working capital, and relatively little debt.
In some cases, companies de-list because they simply don't have the money to pay the filing costs, or they can't file on time due to discrepancies in their accounting, or other issues -- you should be familiar with these types of situations, as you have owned companies where this sort of thing happened.
In the case of AYSI, it appears that they decided to de-list because they weren't getting any benefit out of their OTC BB listing.
In our last conversation, AYSI's CEO and CFO expressed frustration with how the market was valuing their company, and they had a point: why should a profitable, growing company be given a Depression-era valuation? I guess they figured that valuation didn't justify paying the compliance costs associated with an OTC BB listing.
